RCT: Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
2 Jun, 2022 | 10:49h | UTCDurvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer – NEJM Evidence
Commentary on Twitter
Durvalumab, with gemcitabine plus cisplatin, increased median overall survival, 12.8 months versus 11.5 months, in patients with previously untreated unresectable, recurrent or metastatic biliary tract cancer. https://t.co/SaeUxfGfWd#OncTwitter #MedTwitter #Cholangiocarcinoma pic.twitter.com/NZeVljWnyu
— NEJM Evidence (@NEJMEvidence) June 1, 2022